Navigation Links
Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion
Date:7/29/2011

er of 2010.

Product Sales Performance Total product sales increased 8 percent to $3,893 million in the second quarter of 2011 versus $3,613 million in the second quarter of 2010.  U.S. product sales increased 7 percent to $2,975 million in the second quarter of 2011 versus $2,787 million in the second quarter of 2010.  International sales increased 11 percent to $918 million in the second quarter of 2011 versus $826 million in the second quarter of 2010.  Excluding the $34 million favorable impact of foreign exchange in the second quarter of 2011, both total product sales and international product sales increased 7 percent.

Aranesp® (darbepoetin alfa) sales decreased 3 percent to $585 million in the second quarter of 2011 versus $603 million in the second quarter of 2010.  U.S. Aranesp sales decreased 10 percent to $241 million in the second quarter of 2011 versus $267 million in the second quarter of 2010, due principally to a mid-teens percentage point decrease in unit demand, offset partially by an increase in the average net sales price.  This sales decrease reflects an overall decline in the segment.  International Aranesp sales increased 2 percent to $344 million in the second quarter of 2011 versus $336 million in the second quarter of 2010.  Excluding the $10 million favorable impact of foreign exchange in the second quarter of 2011, international Aranesp sales decreased 1 percent due principally to a low single-digit percentage point decrease in the average net sales price, substantially offset by an increase in unit demand.  This sales decrease reflects an overall decline in the segment, largely offset by an increase in share and expansion into newer territories. 

EPOGEN® (Epoetin alfa) sales decreased 17 percent to $543 million in the second quarter of 2011 versus $657 million in the second quarter of 2010, due primarily to a decline in unit demand. The decrease in unit demand
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
2. Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21
3. Amgen’s First Quarter 2011 Revenue Increased 3 Percent to $3.7 Billion
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... BOCA RATON, Fla. , July 29, 2015 ... immediate launch of Azelastine HCl Nasal Solution, 0.1%. The ... this Abbreviated New Drug Application (ANDA), which is ... Meda Pharmaceuticals. Azelastine hydrochloride nasal solution (nasal spray) ... on June 2015 IMS Health sales data.  Azelastine ...
(Date:7/29/2015)... , July 29, 2015 ... research report "Global Industry Insight: Microfluidic Devices ... market overview, trends, DRO analysis, market segmentation, ... developments, competitive scenario and top competitor profiles. ... Microfluidic devices  ...
(Date:7/29/2015)... , July 29, 2015 Commenting ... transaction closed, CFO Simon Dingemans reveals sales ... are performing in line with expectations. Ahead of a ... to sustainable innovation. The interview and transcript ... MerchantCantos produces in-depth interviews, documentaries and webcasts with senior ...
Breaking Medicine Technology:Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 2Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 3Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 4Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 5
... The drug imatinib,mesylate, more commonly known as Gleevec(R), ... with an advanced form of chronic myeloid leukemia,(CML), according ... of the American Society of Hematology., A team ... drug,s,creator, Brian Druker, MD, followed 454 patients with chronic-phase ...
... ActivBiotics, Inc. today,announced the results of its ... rifalazil in the treatment of intermittent claudication,associated ... demonstrated,that treatment for two months with the ... significant improvement in walking distance,claudication onset times, ...
Cached Medicine Technology:Leukemia Drug Proves Safe and Effective Over the Long Term 2Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 2Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 3
(Date:7/29/2015)... ... ... privileged to announce that U.S. News & World Report has ranked the USC ... nation for 2015-2016. This marks the 21st consecutive year that the USC Eye Institute has ... to be included in the top 10 ophthalmology hospitals by U.S. News & World Report,” ...
(Date:7/29/2015)... ... July 29, 2015 , ... Inspired by a successful teaching ... W. Meier M.D., a prominent orthopedic surgeon and regenerative medicine expert in Beverly ... need. , “We are thrilled for this opportunity to offer prolotherapy treatments for ...
(Date:7/29/2015)... ... 2015 , ... Stealth Therapeutics Inc. announced today that it ... Invisiport at Wheaton Franciscan Healthcare in Milwaukee, Wis. The Invisiport product line, which ... alternative to traditional chest ports and peripherally inserted central catheters (PICCs). It is ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... decision from the Judicial Panel on Multidistrict Litigation (JPML), according to court documents.* ... research at their website, the Zofran Birth Defects Lawsuit Center. , GlaxoSmithKline, the ...
(Date:7/29/2015)... ... 2015 , ... The Woodlands and Spring Fit Body Boot Camps have implemented ... causes each month. The new system will track each time a client uses social ... each facility, the boot camps will donate 20 cents to a selected charity. , ...
Breaking Medicine News(10 mins):Health News:21 Years & Counting: The USC Eye Institute Ranks in the Top 10 Ophthalmology Hospitals in America 2Health News:21 Years & Counting: The USC Eye Institute Ranks in the Top 10 Ophthalmology Hospitals in America 3Health News:Orthopedic Surgeon Announces New Pro Bono Prolotherapy and Regenerative Medicine Clinic for Underserved Communities in Los Angeles 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 4Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 2Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 3
... of a certain cell in the immune system may help ... the Program in Cellular and Molecular Medicine and the Immune ... 21 in Nature Immunology , they show, for the ... cells (DCs) capture flu viruses and show them to B-lymphocytes, ...
... provide target for future treatments, researchers say , MONDAY, ... variations linked with an increased risk for lung cancer ... research team analyzed DNA from more than 1,000 people ... smoked and found strong evidence that two variations in ...
... ... ... ... /PRNewswire/ - Haemacure Corporation (TSX:HAE) announces that it has obtained authorization from the Superior Court of the Province of Québec to sell its assets to Angiotech Pharmaceuticals, Inc., a ...
... MAYO Communications has been retained to promote the first MAMMOJAM 2010 set for Thursday, April 1, 2010 , at the newly opened Rise Club , 6801 W. Hollywood Blvd., ... , ... ... ...
... ... innovator in the live archiving space, MessageSolution is the first on-premise and SaaS archiving ... including Exchange, Domino GroupWise, file systems and SharePoint, delivering compliance archiving for all Unix/Linux-based ... ...
... ... surgery in Honolulu, Hawaii , is unveiling a new, interactive website geared toward educating web ... ... suffer from morbid obesity, weighing 80 pounds or more over the average for their size ...
Cached Medicine News:Health News:Poorly understood cell plays role in immunity against the flu 2Health News:Poorly understood cell plays role in immunity against the flu 3Health News:Court Authorizes Haemacure to Sell its Assets and Grants a Second Extension to Make a Proposal to its Creditors 2Health News:MAYO Communications Retained by MAMMOJAM 2010 Dr. Susan Love Research Foundation Event 2Health News:MAYO Communications Retained by MAMMOJAM 2010 Dr. Susan Love Research Foundation Event 3Health News:MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010 2Health News:MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010 3Health News:MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010 4Health News:MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010 5Health News:MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010 6Health News:Honolulu, Hawaii Bariatric Surgery Practice Launches New Website to Reach Out to Patients Fighting Morbid Obesity 2Health News:Honolulu, Hawaii Bariatric Surgery Practice Launches New Website to Reach Out to Patients Fighting Morbid Obesity 3
... Since its introduction to the market, the ... has proven itself as a highly efficient ... fields of urology and gastroenterology. The new ... been technically further developed and improved in ...
ELVeS™ (Endo Laser Vein System) from biolitec is a versatile, easy to use & complete system that allows you to treat all conditions resulting from venous incompetence. (ELVeS has FDA clearance ...
One piece, 100% fused silica construction offers low scatter and high efficiency...
The new series of Steris Power-lift Stirrups incorporate all of the proven clinical benefits of Allen-style booted stirrups: maximum safety for the patient, ease of setup for your staff, impressive v...
Medicine Products: